Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...
Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...
Leaked Pfizer Phase 1 trial shows mevrometostat plus Xtandi reduced prostate cancer progression risk by 49%. Data sparked ...
An integrated strategy for the prevention, support and treatment of prostate cancer was launched today. The plan, which was ...
A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...
Sunday Trust on MSN1d
Prostate Cancer: A Silent BattleFebruary 4 is observed as World Cancer Day. And one of the challenges men face is prostate cancer. Statistics show that, globally, approximately 1 in 8 men will be diagnosed with prostate cancer at ...
Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.
A mother of two with many dreams, she discovered a lump in her breast. A subsequent diagnosis confirmed her worst fear: ...
When prostate cancer metastasizes, spreads outside of the prostate itself, it typically affects the structures in its immediate vicinity. Structures near the prostate likely to be involved include ...
At the New Mexico Cancer Center in Albuquerque, groundbreaking treatments and compassionate care are helping change the lives ...
7d
allAfrica.com on MSNAstrazeneca Reaffirms Commitment to Cancer Care On World Cancer DayAstraZeneca has reinforced its commitment to advancing cancer care through early detection, innovative treatments, and equitable healthcare access in recognition of World Cancer Day 2025 under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results